SAB Biotherapeutics, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsSAB Biotherapeutics is a clinical-stage biopharmaceutical company developing a human immunoglobulin G (hIgG) platform using transchromosomic cattle, with lead candidate SAB-142 for type 1 diabetes.
What they do
SAB Biotherapeutics uses genetically engineered transchromosomic cattle (Tc-Bovine) to produce multi-specific, high-potency human immunoglobulin G (hIgG) without human plasma donors. The company's lead candidate, SAB-142, is a fully human anti-thymocyte globulin (hATG) in clinical development for autoimmune type 1 diabetes (T1D), with a mechanism of action analogous to rabbit ATG. The platform also has potential to generate other therapeutic candidates targeting immune and autoimmune disorders, with a polyclonal antibody approach that the company says has no biosimilar pathway.
Revenue drivers
- No commercial products — The company is clinical-stage with no approved products; revenue was $0.00 in 2025, down from $1.3M in 2024 and $2.2M in 2023, historically from government or collaboration agreements.
- SAB-142 (lead candidate) — Potential disease-modifying therapy for Stage 3 T1D; in Phase 2b (SAFEGUARD study) with first patient dosed December 2025; no revenue yet.
- Platform technology — Tc-Bovine platform can generate hIgG for multiple targets; potential for pipeline expansion but no current revenue generation.
Recent performance
For fiscal year 2025, revenue was $0.00, net income was $13.3M (a turnaround from a $34.1M loss in 2024), but diluted EPS was -$0.79. Operating cash flow worsened to -$44.8M in 2025 from -$34.3M in 2024. As of June 30, 2026, total assets were $238.2M, liabilities $23.4M, and cash and equivalents were $8.3M. The company announced positive topline data from the Phase 1 SAB-142 trial in January 2025 and December 2025.
Strategy
The company is focused on advancing SAB-142 through pivotal Phase 2b (SAFEGUARD) clinical development, with plans to use the data as supportive evidence for future regulatory approval. It aims to expand its pipeline into other autoimmune and immune disorders using its Tc-Bovine platform. Management highlights the platform's ability to produce disease-targeted hIgG without human donors and sees no biosimilar pathway as a competitive barrier. The company is also working with regulators (FDA, MHRA, TGA) to establish a regulatory path for T1D indications.
Risks
- Clinical-stage uncertainty — All product candidates are in preclinical or clinical development; there is no guarantee of successful development or regulatory approval.
- Limited liquidity — Cash and equivalents were only $8.3M as of June 30, 2026; ongoing operating losses and negative operating cash flow could require additional financing.
- No revenue — The company has no commercial products and revenue is zero; it has incurred significant losses since inception and may not achieve profitability.
- Regulatory and manufacturing risks — SAB-142 relies on a novel production platform; any delays or failures in obtaining required approvals or scaling production could harm the business.
Outlook
Management expects to continue advancing SAB-142 in the Phase 2b SAFEGUARD study, which initiated in Q3 2025. They intend to use the study data as supportive evidence for future regulatory approval, as confirmed with the FDA in May 2025. The company also plans to expand its pipeline into other immunology indications using the Tc-Bovine platform. Near-term focus remains on executing clinical development and managing cash resources, though no specific revenue guidance is provided.